Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab monotherapy versus tocilizumab plus methotrexate maintenance in rheumatoid arthritis with low disease activity
2011-001626-15Phase 3Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab monotherapy with Tocilizumab plus methotrexate (2 arms). Primary endpoint: Change in DAS28 from randomization at week 16 to end of treatment at week 28. Started Oct 2011; status: completed.
02
Drugs
tocilizumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-001626-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001626-15.